Download PDF
Thromb Haemost 1977; 38(02): 0514-0523
DOI: 10.1055/s-0038-1651858
Original Article
Schattauer GmbH

Treatment of Anti-Factor VIII Antibodies

Philip M. Blatt
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
,
Gilbert C. White II
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
,
Campbell W. McMillan
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
,
Harold R. Roberts
1   Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 10 May 1977

Accepted 24 May 1977

Publication Date:
04 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Bleeding episodes in patients with hemophilia A with anti-factor VIII antibodies are frequently difficult to treat. Factor VIII concentrates administered by continuous infusion or prothrombin complex concentrates (PCC) have been used for treatment. Hemophilia A patients with inhibitors who respond to factor VIII concentrates generally have low to moderate inhibitor titers (generally less than 20 Bethesda units). Those patients who receive PCC are quite difficult to evaluate but promising clinical responses have clearly been observed. This paper describes our experience with both modalities of therapy and will offer specific guidelines for such therapy.

 

  • References

  • 1 Abildgaard C. F, Bruton M, Harrison J. 1976; Prothrombin complex concentrates (Kon¯yne) in the treatment of hemophilic patients with factor VIII inhibitors. Journal of Pediatrics 88: 200.
    CrossrefPubMedGoogle Scholar
  • 2 Allain J. P, Krieger G. R. 1975; Prothrombin complex concentrate in treatment of classical hemophilia with factor VIII antibody. Lancet II: 1203.
    PubMedGoogle Scholar
  • 3 Blatt P. M, Lundblad R. L, Kingdon H. S, McLean G, Roberts H. R. 1974; Thrombogenic materials in prothrombin complex concentrates. Annals of Internal Medicine 81: 766.
    CrossrefPubMedGoogle Scholar
  • 4 Cederbaum A. I, Blatt P. M, Roberts H. R. 1976; Intravascular coagulation with the use of human prothrombin complex concentrates. Annals of Internal Medicine 84: 683.
    CrossrefPubMedGoogle Scholar
  • 5 Davey R. J, Shashaty G. G, Rath C. E. 1976; Acute coagulopathy following infusion of prothrombin complex concentrate. American Journal of Medicine 60: 719.
    CrossrefPubMedGoogle Scholar
  • 6 Edson J. R. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 403.
    CrossrefPubMedGoogle Scholar
  • 7 Elsinger F. 1975 Shortening of clotting times of hemophilia A plasma with inhibitor induced by activated factor IX concentrates. Vth Congress of the International Society of Thrombosis and Haemostasis, Paris. July 1976.
    PubMedGoogle Scholar
  • 8 Faria R, Fiumara N. J. 1972; Hepatitis B associated with kon¯yne. New England Journal of Medicine 287: 358.
    PubMedGoogle Scholar
  • 9 Fekete L. F, Holst S. L, Peetoom F, Deveber L. L. 1972 »Auto« – Factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. Presented at the Fourteenth International Congress of Hematology, Sao Paulo, Brazil . July 1972, abstract #295.
    PubMedGoogle Scholar
  • 10 Grammens G. L, Breckenridge R. T. 1974; Complications with Christmas factor (factor IX) concentrates. Annals of Internal Medicine 80: 666.
    CrossrefPubMedGoogle Scholar
  • 11 Hoofnagle J. H, Aronson D. L, Roberts H. R. 1975; Serologic evidence for hepatitis B virus infection in patients with hemophilia B. Thrombosis et Diathesis Haemorrhagica 33: 606.
    PubMedGoogle Scholar
  • 12 Kasper C, Kipnis S. 1972; Hepatitis and clotting factor concentrates. Journal of the American Medical Association 221: 510.
    PubMedGoogle Scholar
  • 13 Kasper C. K. 1973; Post-operative thromboses in hemophilia B. New England Journal of Medicine 289: 160.
    PubMedGoogle Scholar
  • 14 Kasper C. K. 1975; Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica 33: 640.
    PubMedGoogle Scholar
  • 15 Kasper C. K, Aledort L. M, Counts R. B, Edson J. R, Fratantoni J, Green D, Hampton J. W, Hilgartner M. W, Lazerson J, Levine P. H, McMillan C. W, Pool J. G, Shapiro S. S, Shulman N. R, Van Eys J. 1975; A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica 34: 869.
    PubMedGoogle Scholar
  • 16 Kasper C. K, Feinstein D. I. 1976; Rising factor VIII inhibitor titers after Kon¯yne factor IX complex. New England Journal of Medicine 295: 505.
    CrossrefPubMedGoogle Scholar
  • 17 King E. G, Clarke M. E, Buchanan D. I. 1972; Acute anemia with factor VIII therapy. Annals of Internal Medicine 77: 323.
    CrossrefPubMedGoogle Scholar
  • 18 Kingdon H. S. 1970; Hepatitis after Kon¯yne. Annals of Internal Medicine 73: 656.
    PubMedGoogle Scholar
  • 19 Kurczynski E. M, Penner J. A. 1974; Activated prothrombin concentrate for patients with factor VIII inhibitors. New England Journal of Medicine 291: 164.
    CrossrefPubMedGoogle Scholar
  • 20 Langdell R. D, Wagner R. H, Brinkhous K. M. 1953; Effect of antihemophilic factor on one-stage clotting tests. Journal of Laboratory Clinical Medicine 41: 637.
    PubMedGoogle Scholar
  • 21 Lusher J. M, Ravindranath Y, Arciniegas E, Green E. 1974; Open heart surgery in a hemophiliac patient. American Journal of Diseases of Children 127: 708.
    CrossrefPubMedGoogle Scholar
  • 22 Mannucci P. M, Bader R, Ruggeri Z. M. 1976; Concentrates of clotting – factor IX. Lancet I: 41.
    PubMedGoogle Scholar
  • 23 Marchesi S. L, Burney R. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 403.
    CrossrefPubMedGoogle Scholar
  • 24 McMillan C. W, Webster W. P, Roberts H. R, Blythe W. B. 1970; Continuous intravenous infusion of factor VIII in classic hemophilia. British Journal of Haematology 18: 659.
    CrossrefPubMedGoogle Scholar
  • 25 Orringer E. P, Koury M. J, Blatt P. M, Roberts H. R. 1976; Hemolysis caused by factor VIII concentrates. Archives of Internal Medicine 136: 1018.
    CrossrefPubMedGoogle Scholar
  • 26 Penner J. A, Kelly P. E. 1975; Management of patients with factor VIII or IX inhibitors. Seminars in Thrombosis and Hemostasis 1: 386.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Kelly P, Penner J. A. 1976; Management with prothrombin complex concentrates. Journal of the American Medical Association 236: 2061.
    CrossrefPubMedGoogle Scholar
  • 28 Rosati L. A, Barnes B, Oberman H. A, Penner J. A. 1970; Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations. Transfusion 10: 139.
    CrossrefPubMedGoogle Scholar
  • 29 Roberts H. R, Scales M. B, Madison J. T, Webster W. P, Penick G. D. 1965; A clinical and experimental study of acquired inhibitors to factor VIII. Blood 26: 805.
    PubMedGoogle Scholar
  • 30 Roberts H. R, Blatt P. M. 1975; Post-transfusion hepatitis following the use of prothrombin complex concentrates. Thrombosis et Diathesis Haemorrhagica 33: 610.
    PubMedGoogle Scholar
  • 31 Seeler R. A. 1972; Hemolysis due to anti-A and anti-B in factor VIII preparations. Archives of Internal Medicine 130: 101.
    CrossrefPubMedGoogle Scholar
  • 32 Steinberg M. H, Dreiling B. J. 1973; Vascular lesions in hemophilia B. New England Journal of Medicine 289: 592.
    PubMedGoogle Scholar
  • 33 Sultan Y, Brouet J. C, Debre P. 1974; Treatment of inhibitors to factor VIII with activated prothrombin concentrate. New England Journal of Medicine 291: 1087.
    PubMedGoogle Scholar
  • 34 Triantaphyllopoulos D. C. 1972; Intravascular coagulation following injection of prothrombin complex. American Journal of Clinical Pathology 57: 603.
    CrossrefPubMedGoogle Scholar
  • 35 White II G. C, Lundblad R. L, Blatt P. M, Kingdon H. S, Roberts H. R. 1975 Effects of deliberately activated and partially activated prothrombin complex concentrates on normal plasma and on hemophilia A plasma containing an inhibitor of factor VIII. Eighteenth Annual Meeting of the American Society of Hematology, Dallas, Texas..
    PubMedGoogle Scholar